IPWSO welcomes US FDA approval for first PWS hyperphagia treatment
The US FDA has approved VYKAT XR, a novel treatment for hyperphagia in Prader-Willi syndrome, marking a significant milestone in the management of the condition. This breakthrough approval follows extensive evaluation and data from clinical trials, paving the way for improved access to life-changing treatments globally.